SAVA, GIANNI
 Distribuzione geografica
Continente #
NA - Nord America 24.060
EU - Europa 11.572
AS - Asia 10.658
SA - Sud America 1.168
AF - Africa 260
Continente sconosciuto - Info sul continente non disponibili 32
OC - Oceania 20
Totale 47.770
Nazione #
US - Stati Uniti d'America 23.826
SG - Singapore 4.036
CN - Cina 2.718
UA - Ucraina 1.918
SE - Svezia 1.891
PL - Polonia 1.469
IT - Italia 1.321
DE - Germania 1.289
HK - Hong Kong 1.081
BR - Brasile 934
VN - Vietnam 924
KR - Corea 726
FI - Finlandia 704
RU - Federazione Russa 693
GB - Regno Unito 640
FR - Francia 571
TR - Turchia 379
BG - Bulgaria 308
IE - Irlanda 301
BD - Bangladesh 186
IN - India 156
NL - Olanda 154
CA - Canada 114
AR - Argentina 89
MA - Marocco 81
MX - Messico 64
IQ - Iraq 60
CH - Svizzera 57
SA - Arabia Saudita 51
JP - Giappone 49
ID - Indonesia 47
ES - Italia 42
ZA - Sudafrica 40
BE - Belgio 33
EU - Europa 30
PK - Pakistan 30
AT - Austria 29
EC - Ecuador 29
SN - Senegal 28
KE - Kenya 26
UZ - Uzbekistan 26
VE - Venezuela 25
RO - Romania 24
CO - Colombia 23
EG - Egitto 23
TH - Thailandia 23
CL - Cile 20
PH - Filippine 20
PY - Paraguay 18
BA - Bosnia-Erzegovina 15
CZ - Repubblica Ceca 15
TW - Taiwan 15
MY - Malesia 14
PT - Portogallo 14
AE - Emirati Arabi Uniti 13
KZ - Kazakistan 13
DK - Danimarca 12
JO - Giordania 12
LT - Lituania 12
RS - Serbia 12
TN - Tunisia 12
AU - Australia 11
BO - Bolivia 11
DZ - Algeria 11
UY - Uruguay 11
HN - Honduras 10
AZ - Azerbaigian 9
IL - Israele 9
IR - Iran 9
AL - Albania 8
GR - Grecia 8
NZ - Nuova Zelanda 8
CI - Costa d'Avorio 7
DO - Repubblica Dominicana 7
GE - Georgia 7
JM - Giamaica 7
NP - Nepal 7
ET - Etiopia 6
HR - Croazia 6
HU - Ungheria 6
NG - Nigeria 6
OM - Oman 6
PE - Perù 6
TT - Trinidad e Tobago 6
BB - Barbados 5
LB - Libano 5
QA - Qatar 5
SI - Slovenia 5
BH - Bahrain 4
CR - Costa Rica 4
GA - Gabon 4
GT - Guatemala 4
NI - Nicaragua 4
LK - Sri Lanka 3
MD - Moldavia 3
PS - Palestinian Territory 3
AO - Angola 2
BW - Botswana 2
BY - Bielorussia 2
CG - Congo 2
Totale 47.724
Città #
Woodbridge 2.449
Singapore 2.401
Ann Arbor 2.360
Fairfield 1.903
Ashburn 1.899
Houston 1.691
Jacksonville 1.646
San Jose 1.268
Chandler 1.267
Warsaw 1.159
Wilmington 1.112
Hong Kong 1.056
Seattle 831
Hefei 799
Seoul 711
Cambridge 647
Beijing 634
Princeton 574
Boardman 477
Chicago 462
Sofia 307
Dublin 297
Ho Chi Minh City 293
Columbus 291
Los Angeles 285
Zgierz 281
Izmir 277
Lauterbourg 261
Santa Clara 244
The Dalles 237
Moscow 230
Dallas 224
Dearborn 217
Hanoi 217
Milan 211
Buffalo 185
Trieste 176
San Diego 138
Helsinki 114
Düsseldorf 109
London 81
Frankfurt am Main 74
New York 73
Munich 68
São Paulo 67
Council Bluffs 66
Casablanca 58
Falls Church 54
Verona 54
Guangzhou 53
Kocaeli 51
Phoenix 50
Norwalk 47
Amsterdam 46
Redwood City 46
Kunming 45
Shanghai 45
Orem 44
Bern 43
Da Nang 42
Nanjing 42
Bremen 41
Mestre 40
Rio de Janeiro 39
Tokyo 39
Turku 38
Salt Lake City 37
Des Moines 35
Tianjin 34
Jinan 33
Miano 33
Haiphong 32
Brussels 29
Denver 29
Chennai 28
Dakar 28
Montreal 28
Atlanta 27
San Francisco 25
Brooklyn 24
Hangzhou 23
Nairobi 23
North Bergen 23
Tashkent 23
Toronto 23
Poplar 22
Porto Alegre 22
Rome 22
Mexico City 21
Zhengzhou 21
Andover 20
Johannesburg 20
Redondo Beach 20
Elk Grove Village 19
Jeddah 19
Tampa 19
Vienna 19
Baghdad 18
Belo Horizonte 18
Fuzhou 18
Totale 32.121
Nome #
The differential distribution of RAPTA-T in non-invasive and invasive breast cancer cells correlates with its anti-invasive and anti-metastatic effects 648
Effects of Two Fullerene Derivatives on Monocytes and Macrophages 472
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 407
Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis 375
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 370
Chemical and Molecular Approach to Tumor Metastases 349
A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival 324
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. 312
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 292
New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents. 276
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 256
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy 250
Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii 248
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 247
A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results 244
Antitumor action of mer-trichlorobis(dimethyl sulfoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma 242
Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide 240
Antimetastatic Action and Lymphocyte Activation by the Modified Lysozyme Lyso-M-PEG in Mice with Mca Mammary Carcinoma 240
Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK 236
Antitumor properties of ruthenium(II)-dimethylsulfoxide complexes in the Lewis lung carcinoma system 234
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)(Im)]. 234
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 234
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms 231
Effects of lysozyme on spleen and lungs in mice with Lewis lung carcinoma 229
Ruthenium(III) complexes as antineoplastic agents. 228
Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma 228
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure 226
Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in theLewis lung carcinoma system. 225
trans-Ru(II)dimethylsulfoxides: antineoplastic action on mouse tumors 225
Antineoplastic effects of mer-RuCl3(DMSO)2(NH3) against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. 223
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma 223
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 223
Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review 220
Dual action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen 219
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 219
Antiinflammatory action of hydrosoluble dimethyltriazenes on the carrageenin-induced edema in guinea pigs 219
Tumor inhibition and effects on host survival time by rutheniumIII andrhodiumIII complexes with dimethylsulphoxide ligands. 218
Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. 216
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 214
Antileukemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline 214
Antimetastatic action and toxicity on healty tissues of Na[trans-RuCl4(DMSO)Im] in the mouse. 213
Complessi di Rutenio con elevata attività antitumorale 212
Antimetastatic action and toxicity on healthy tissues ofNa[trans-RuCl4(DMSO)Im] in the mouse. 211
Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice 211
Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A 210
Antimetastatic action of the prostacyclin analog Iloprost in the mouse 210
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 208
Biochemical and biological characteristics of leucocyte proteinase inhibitors. 207
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy 206
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 206
Complessi trans di rutenio come agenti antineoplastici 205
Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice 205
Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. 205
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(μ-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation 204
Free exchange across cells,and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A(imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate)ON KB Tumor cells. 203
Antimetastatic effects of N-diazoacetyl-glycine derivatives in C57BL mice. 203
Hydrophilic polymer coated monodispersed Fe3O4 nanostructures and their cytotoxicity 203
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 202
Ruthenium complexes can target determinants of tumour malignancy 200
Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes 200
Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A 200
The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes 199
Antimetastatic effects and tumor proteinase inhibition by spleen intracellular inhibitors of neutral proteinases. 199
Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells 199
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 197
Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride 197
Human recombinant lysozyme downregulates advanced glycan endproduct-induced interleukin-6 production and release in an in vitro model of human proximal tubular epithelial cells 197
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A 196
Half-sandwich RuIIsingle bond[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity 196
Metal-based antitumour drugs in the post-genomic era: what comes next? 196
Antineoplastic action of egg-white lysozyme on the growth of MCa mammary carcinoma and TLX5 lymphoma in the CBA mouse. 195
A review on usnic acid, an interesting natural compound 195
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. 195
Methodologic problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor. 195
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 195
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 194
Na[trans-RuCl4(DMSO)(Im)]*2DMSO - antimetastatic ruthenium agent 194
Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. 194
Microcapsule a doppio strato di polisaccaridiutilizzabili come veicoli per la somministrazione oraledi sostanze biologicamente attive 193
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir 193
Antineoplastic action of p-(3-methyl-1-triazeno) benzoic acid potassium salt, monomethylderivative of the antimetastatic compound DM-COOK 193
Effects of trans-RuCl2 (DMSO)4 on B16 melanoma in mice. 190
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion. 190
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. 189
Chemical, biological and antitumor properties of ruthenium-dimethylsulfoxide complexes 188
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 188
Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme 188
Investigation on the oxidative N-demethylation of aryltriazenes in vitro 187
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq 187
Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice 187
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 186
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA 186
Antitumor action of rhodium(I) and iridium(I) complexes 186
Anticancer ruthenium complexes 186
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 186
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 185
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 185
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers 184
Biological and technological evaluation of PVC containers for human blood and blood components 184
Stimulation of GALT and Activation of Mesenteric Lymphonode Lymphocytes by a Modifìed Iysozyme in CBA Mice with Mca mammary carcinoma 184
Totale 22.512
Categoria #
all - tutte 140.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.761


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021446 0 0 0 0 0 0 0 0 0 0 0 446
2021/20223.230 103 253 187 463 49 257 137 116 386 345 200 734
2022/20233.888 426 429 284 486 445 737 9 354 474 23 158 63
2023/20241.932 163 134 109 112 221 92 245 504 29 35 141 147
2024/20255.277 96 157 510 422 495 511 430 310 720 559 441 626
2025/202612.973 1.275 830 1.086 1.082 1.082 1.316 2.023 454 1.381 1.668 435 341
Totale 48.475